Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Free Cash Flow (2016 - 2025)

Karyopharm Therapeutics' Free Cash Flow history spans 14 years, with the latest figure at -$11.8 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 54.08% year-over-year to -$11.8 million; the TTM value through Dec 2025 reached -$75.4 million, up 40.95%, while the annual FY2025 figure was -$75.4 million, 40.95% up from the prior year.
  • Free Cash Flow reached -$11.8 million in Q4 2025 per KPTI's latest filing, down from -$5.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $25.3 million in Q4 2021 to a low of -$59.3 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$27.6 million, with a median of -$26.3 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: surged 182.16% in 2021, then crashed 206.23% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at $25.3 million in 2021, then plummeted by 206.23% to -$26.8 million in 2022, then surged by 30.76% to -$18.6 million in 2023, then plummeted by 38.59% to -$25.8 million in 2024, then surged by 54.08% to -$11.8 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Free Cash Flow are -$11.8 million (Q4 2025), -$5.9 million (Q3 2025), and -$18.7 million (Q2 2025).